Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.